

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	ATTORNEY DOCKET NO. CONFIRMATION NO.	
09/639,207		08/14/2000	Parsa Kazemi-Esfarjani	06618-686001	06618-686001 9459	
20985	7590	12/09/2003		EXAMINER		
FISH & RI		•	SULLIVAN, DANIEL M			
12390 EL C SAN DIEG				ART UNIT PAPER NUMBER		
·				1636		

DATE MAILED: 12/09/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>\'</b>			Ü			
	Application No.	Applicant(s)				
	09/639,207	KAZEMI-ESFARJANI ET	AL.			
Office Action Summary	Examiner	Art Unit				
TI MALL INO DATE of this assumption to	Daniel M Sullivan	1636				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	corresponaence adaress -	-			
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailling date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).  Status	36(a). In no event, however, may a reply be tir within the statutory minimum of thirty (30) day vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communica D (35 U.S.C. § 133).	tion.			
1)⊠ Responsive to communication(s) filed on <u>15 Se</u>	eptember 2003.					
	action is non-final.					
3) Since this application is in condition for allowar closed in accordance with the practice under E			is is			
Disposition of Claims						
<ul> <li>4)  Claim(s) 26,29-32,34,37-40 and 42-79 is/are pending in the application.</li> <li>4a) Of the above claim(s) 47-49 and 51-79 is/are withdrawn from consideration.</li> <li>5)  Claim(s) 26,29-32,34,37-40 and 50 is/are allowed.</li> <li>6)  Claim(s) 42 and 43 is/are rejected.</li> <li>7)  Claim(s) 44-46 is/are objected to.</li> <li>8)  Claim(s) are subject to restriction and/or election requirement.</li> </ul>						
Application Papers						
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex	epted or b) objected to by the drawing(s) be held in abeyance. Se ion is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.12				
Priority under 35 U.S.C. §§ 119 and 120						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of 13) Acknowledgment is made of a claim for domestic since a specific reference was included in the first 37 CFR 1.78.  a) The translation of the foreign language pro 14) Acknowledgment is made of a claim for domestic reference was included in the first sentence of the	s have been received. s have been received in Applicative documents have been received in Applicative (PCT Rule 17.2(a)). of the certified copies not received priority under 35 U.S.C. § 119(at sentence of the specification of the certification of the specification application has been received priority under 35 U.S.C. §§ 120	on No ed in this National Stage ed. e) (to a provisional applic in an Application Data S eeived. and/or 121 since a spec	heet.			
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)  J.S. Patent and Trademark Office	5) Notice of Informal F	(PTO-413) Paper No(s) latent Application (PTO-152)				

PTOL-326 (Rev. 11-03)

Application/Control Number: 09/639,207

Art Unit: 1636

#### DETAILED ACTION

This Office Action is a reply to the "AMENDMENT" of 15 September 2003 (hereinafter, 15 September Paper) filed in response to the Non-Final Office Action mailed 19 June 2003 (hereinafter, 19 June Office Action). Claims 26, 29-35, 37-40, 42-46 and 50 were considered in the 19 June Office Action. Claims 33 and 35 were canceled and claims 26, 34, 37, 39 and 50 were amended in the 15 September paper. Claims 26, 29-32, 34, 37-40 and 42-79 are pending, claims 47-49 and 51-79 are withdrawn from consideration. Claims 26, 29-32, 34, 37-40, 42-46 and 50 are presently under consideration.

#### Response to Amendment

### Claim Rejections - 35 USC § 112

Claims 42 and 43 stand rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement for reasons of record and herein below in the response to arguments.

### Claim Rejections - 35 USC § 103

Rejection of claims 26, 29-34, 37-40 and 50 under 35 U.S.C. 103(a) as being unpatentable over Warrick *et al.* as evidenced by Paulson is withdrawn.

Rejection of claims 26 and 42 under 35 U.S.C. 103(a) as being unpatentable over Warrick et al. as evidenced by Paulson and in view of Rørth is withdrawn.

Art Unit: 1636

#### Response to Arguments

Claims 42 and 43 were rejected as lacking adequate written description for a genus of *D. melanogaster* comprising a marker located adjacent to or inserted into any gene whose expression or activity increases or decreases polyglutamine toxicity in the animal. In response to the rejection of record, Applicant urges, because claim 26 has not been rejected as lacking adequate written description, claims 42 and 43, which depend from claim 26 and incorporate additional elements, must also satisfy the written description requirement. This argument has been fully considered but is not deemed persuasive because it is the additional elements recited in claims 42 and 43 that are not adequately described. Claim 26 has not been rejected because the transgenic *D. melanogaster* of the claim is not limited to comprising a marker located adjacent to or inserted into any gene whose expression or activity increases or decreases polyglutamine toxicity in the animal. Because the *D. melanogaster* of claim 26 is not limited to comprising a marker gene adjacent to or inserted into a gene having the recited activity, the description of claim 26 need not demonstrate possession of the genus at issue in claims 42 and 43.

With regard to claim 43, Applicant further argues that "J domain" containing molecules are both structurally and functionally recognized in the art and therefore demonstrate that the inventors had possession of the claimed invention. This argument is not found persuasive because there is no demonstrated nexus between the "J domain" structure and the recited function of increases or decreases polyglutamine toxicity. That is, the skilled artisan would not recognize the "J domain" structure as a relevant identifying characteristic of the genus of genes capable of increasing or decreasing polyglutamine toxicity.

Application/Control Number: 09/639,207

Art Unit: 1636

Applicant's arguments have been fully considered but are not deemed persuasive individually or as a whole. Therefore claims 42 and 43 stand rejected under 35 U.S.C. §112, first paragraph.

## Allowable Subject Matter

Claims 26, 29-32, 34, 37-40 and 50 are allowed.

Claims 44-46 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

#### Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Application/Control Number: 09/639,207

Art Unit: 1636

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Daniel M Sullivan whose telephone number is 703-305-4448. The examiner can normally be reached on Monday through Friday 8-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel, Ph.D. can be reached on 703-305-1998. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Please note: Art Unit 1636 will be moving to the new USPTO facilities on 14 January 2004. After that date, Examiner Sullivan can be reached at 571-272-0779 and Examiner Yucel can be reached at 571-272-0781.

Anne-Marie Falk, PH.D

PRIMARY EXAMINER

DMS